• Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., said the underwriters of a public offering of its common stock exercised in full their option to purchase an additional 600,000 shares. The total gross proceeds from the offering, including the exercise of the overallotment option, are expected to be $20.2 million. Biocryst said it plans to use net proceeds for general corporate purposes, including funding clinical development of BCX4161, continued development of second-generation hereditary angioedema compounds and pre-commercialization activities related to intravenous peramivir. The offering is expected to close on Aug. 6.

• Sophiris Bio Inc., of San Diego, set the terms for its planned initial public offering and is hoping raise $65 million in an offering of 5 million shares at $13 per share. The company is focused on developing products for the treatment of urological diseases, and its lead product candidate, PRX302, is designed to treat enlarged prostate more effectively without invasive surgery and the sexual side effects that sometimes comes with existing therapy. (See BioWorld Today, Feb. 20, 2013,)